(Q45074391)

9 December 2017

title

Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex). (English)

1 reference

9 December 2017

1 reference

1 reference

1 reference

Kevin Koch

1

1 reference

9 December 2017

Corinne Campanella

2

1 reference

9 December 2017

Charlotte A Baidoo

3

1 reference

9 December 2017

Janet A Manzo

4

1 reference

9 December 2017

Vanessa Z Ameen

5

1 reference

9 December 2017

Kathryn E E Kersey

6

1 reference

9 December 2017

publication date

1 August 2004

1 reference

Digestive Diseases and Sciences

9 December 2017

published in

1 reference

9 December 2017

volume

49

1 reference

9 December 2017

issue

7-8

1 reference

9 December 2017

page(s)

1244-1249

1 reference

Effects of oral contraceptives on hemostasis and thrombosis

9 December 2017

cites work

1 reference

12 December 2020

Gender differences in irritable bowel syndrome

1 reference

12 December 2020

Progestogen metabolism.

1 reference

12 December 2020

Effect of alosetron on theophylline pharmacokinetics

1 reference

12 December 2020

Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children

1 reference

12 December 2020

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Effect of alosetron on the pharmacokinetics of fluoxetine

1 reference

12 December 2020

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Effect of alosetron on the pharmacokinetics of alprazolam

1 reference

12 December 2020

Tentative guidelines and practical suggestions to avoid venous thromboembolism during oral contraceptive therapy

1 reference

12 December 2020

The hypercoagulable state as a risk factor for venous thromboembolism. Part 1.

1 reference

12 December 2020

Biphasic versus triphasic oral contraceptives for contraception

1 reference

12 December 2020

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

12 December 2020

Comparative metabolism of 17α‐ethynyl steroids used in oral contraceptives

1 reference

12 December 2020

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients

1 reference

12 December 2020

Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes

1 reference

12 December 2020

Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450

1 reference

12 December 2020

Reversible ischemic colitis in young women. Association with oral contraceptive use

1 reference

12 December 2020

Venous thromboembolism: pathophysiology, clinical features, and prevention

1 reference

12 December 2020

Elevated hemostatic factor levels as potential risk factors for thrombosis

1 reference

12 December 2020

Oral contraceptive efficacy and antibiotic interaction: a myth debunked

1 reference

12 December 2020

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

12 December 2020

Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms

1 reference

12 December 2020

Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives

1 reference

12 December 2020

10.1023/B:DDAS.0000037819.31817.7C

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

1020601062

0 references

1 reference